BioAge Labs (BIOA) Cash & Equivalents (2023 - 2026)

BioAge Labs has disclosed Cash & Equivalents across 4 years of filings, most recently posting $381.3 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 21.67% year-over-year to $381.3 million; the TTM figure through Jun 2026 stood at $381.3 million (up 21.67% YoY), while the FY2025 annual figure was $188.9 million, down 46.69% from the prior year.
• Cash & Equivalents came in at $381.3 million for Q2 2026 at BioAge Labs, down from $384.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $384.9 million in Q1 2026 to a low of $21.6 million in Q4 2023.
• Average Cash & Equivalents over 4 years is $278.4 million, with a median of $324.0 million recorded in 2024.
• Year-over-year, Cash & Equivalents soared 1537.17% in 2024 and tumbled 46.69% in 2025.
• Over 4 years, Cash & Equivalents stood at $21.6 million in 2023, then soared by 1537.17% to $354.3 million in 2024, then sank by 46.69% to $188.9 million in 2025, then soared by 101.87% to $381.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $381.3 million in Q2 2026, $384.9 million in Q1 2026, and $188.9 million in Q4 2025.